Fibromatosis, Aggressive
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo
Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout